Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Kidney disease Clear all
Completed Not applicable Interventional Results available

Exercise Trial in Chronic Kidney Disease

NCT01462097
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Aerobic exercise training, Health Education
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
60 Years to 85 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 24, 2023 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

NCT00440648
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
sevelamer carbonate, sevelamer hydrochloride, sevelamer hydrochloride, sevelamer carbonate
Drug
Lead sponsor
Genzyme, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
15
States / cities
Mobile, Alabama • Riverside, California • Greenwood Village, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Sep 26, 2026, 5:33 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Jackson Heart Study of Cardiovascular Disease Among African Americans

NCT00005485
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Atherosclerosis, Coronary Disease, Hypertension, Cerebrovascular Disorders
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
35 Years to 84 Years
Enrollment
5,306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2025
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Sep 26, 2026, 5:33 AM EDT
Withdrawn Phase 3 Interventional

Fasiglifam in Type 2 Diabetic Subjects With Chronic Kidney Disease Stage 4 or 5 on Hemodialysis

NCT02015780
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Chronic Kidney Disease
Interventions
Fasiglifam, Placebo, Antihyperglycemic therapy
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
Whittier, California • Westminster, Colorado • Tampa, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2014 · Synced Sep 26, 2026, 5:33 AM EDT
Terminated Phase 3 Interventional Results available

Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy

NCT00318474
View directory record Official record
Conditions
IgA Nephropathy
Interventions
Mycophenolate Mofetil (MMF), MMF Placebo, ACEi, FOS
Drug
Lead sponsor
St. Joseph's Hospital and Medical Center, Phoenix
Other
Eligibility
7 Years to 70 Years
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 6, 2016 · Synced Sep 26, 2026, 5:33 AM EDT
Terminated Early Phase 1 Interventional

CCR2 AAA Pilot Study

NCT04592991
View directory record Official record
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
Aortoiliac Occlusive Disease Group - PET-CT imaging with injection of 64Cu-DOTA-ECL1i, AAA Group- PET-CT imaging with injection of 64Cu-DOTA-ECL1i
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
45 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 14, 2022 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

Oblimersen and Interferon Alfa in Treating Patients With Metastatic Renal Cell Cancer

NCT00059813
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
recombinant interferon alfa, oblimersen sodium, pharmacological study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 25, 2013 · Synced Sep 26, 2026, 5:33 AM EDT
Completed No phase listed Observational

Pioglitazone and Lumbar Bone Marrow Fat in Chronic Kidney Disease

NCT02739750
View directory record Official record
Conditions
Polycystic Kidney Diseases
Interventions
No intervention
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 25, 2022 · Synced Sep 26, 2026, 5:33 AM EDT
Recruiting Phase 2 Interventional

NAD Augmentation in Diabetes Kidney Disease

NCT05759468
View directory record Official record
Conditions
Type2diabetes, Diabetic Kidney Disease
Interventions
Investigational Product - MIB 626, Placebo
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 26, 2026, 5:33 AM EDT
Completed No phase listed Observational Results available

Improving Screening and Therapy for Hispanic/Latinx at Risk for CKD

NCT05734989
View directory record Official record
Conditions
Type 2 Diabetes, Chronic Kidney Diseases
Interventions
BP, HbA1c, PCP Guidelines for Screening and Monitoring Hispanic/Latinx patients for CKD
Diagnostic Test · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Sep 26, 2026, 5:33 AM EDT
Active, not recruiting Phase 3 Interventional

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)

NCT06291376
View directory record Official record
Conditions
Immunoglobulin A Nephropathy, IgAN
Interventions
Ravulizumab, Placebo
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
579 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
39
States / cities
Alabaster, Alabama • Phoenix, Arizona • Los Angeles, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Sep 26, 2026, 5:33 AM EDT
Terminated Phase 3 Interventional

Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis

NCT03710291
View directory record Official record
Conditions
Metabolic Acidosis, Chronic Kidney Disease
Interventions
TRC101, Placebo
Drug
Lead sponsor
Tricida, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
1,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
20
States / cities
Azusa, California • Denver, Colorado • Boca Raton, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2022 · Synced Sep 26, 2026, 5:33 AM EDT
Completed No phase listed Observational

Antenatal Platelet Response On Aspirin and Correlation With HDP (Hypertensive Disorders of Pregnancy)

NCT04295850
View directory record Official record
Conditions
Preeclampsia
Interventions
Aspirin 81 mg
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
10 Years to 60 Years · Female only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 1, 2025 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dietary Oxalate and Innate Immunity in Kidney Stone Disease

NCT04051346
View directory record Official record
Conditions
Kidney Stone
Interventions
Low Oxalate Diet, High Oxalate Diet
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

NCT06150924
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD
Drug
Lead sponsor
Mineralys Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
44
States / cities
Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

Letermovir Versus Valganciclovir to Prevent Human Cytomegalovirus Disease in Kidney Transplant Recipients (MK-8228-002)

NCT03443869
View directory record Official record
Conditions
CMV Disease
Interventions
Letermovir, Valganciclovir, Acyclovir (ACV), Placebo to ACV, Placebo to LET, Placebo to VGCV
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
601 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
27
States / cities
Birmingham, Alabama • Los Angeles, California • Sacramento, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 26, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional

A Study of Participants With Chronic Kidney Disease Previously Treated With REACT

NCT05694169
View directory record Official record
Conditions
Diabetic Kidney Disease, CAKUT, Chronic Kidney Diseases
Interventions
Renal Autologous Cell Therapy (REACT)
Biological
Lead sponsor
Prokidney
Industry
Eligibility
30 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boise, Idaho
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Sep 26, 2026, 5:33 AM EDT
Terminated No phase listed Observational

Von Hippel-Lindau Disease Genetic Epidemiology Study

NCT00001803
View directory record Official record
Conditions
Von Hippel Lindau Disease, Kidney Neoplasms
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years to 100 Years
Enrollment
546 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 12, 2020 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 2 Interventional

Safety and Activity of G-202 in Patients With Clear Cell Renal Cell Carcinoma That Expresses PSMA

NCT02607553
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma
Interventions
G-202
Drug
Lead sponsor
GenSpera, Inc.
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Sep 26, 2026, 5:33 AM EDT
Recruiting Phase 3 Interventional

Patient-driven Management of BP in CKD

NCT05546099
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Self-management of BP medications, Self-monitoring of home BP
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of TMX-049 in Subjects With Type 2 Diabetes and Albuminuria

NCT03449199
View directory record Official record
Conditions
Diabetic Kidney Disease
Interventions
TMX-049, Placebo
Drug
Lead sponsor
Teijin America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
55
States / cities
Flagstaff, Arizona • Mesa, Arizona • Alhambra, California + 41 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2022 · Synced Sep 26, 2026, 5:33 AM EDT
Completed No phase listed Observational

PK-PD Study of Mycophenolic Acid (CellCept) in Pediatric Kidney Transplant Patients

NCT00281619
View directory record Official record
Conditions
Kidney Transplant
Interventions
CellCept (mycophenolate mofetil), Dietary Monitoring, Drug Diary, Blood Sampling
Drug · Behavioral · Procedure
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 17 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 18, 2013 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 4 Interventional Results available

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

NCT01427907
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Calcium acetate oral solution (COS), Sevelamer carbonate
Drug
Lead sponsor
Fresenius Medical Care North America
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
New Haven, Connecticut • North Haven, Connecticut • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 26, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Different Oral Doses of BAY94-8862 in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Nephropathy

NCT01874431
View directory record Official record
Conditions
Diabetic Nephropathies
Interventions
Finerenone (BAY94-8862), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
823 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
15
States / cities
Birmingham, Alabama • Chula Vista, California • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2021 · Synced Sep 26, 2026, 5:33 AM EDT